Clinical Research Directory
Browse clinical research sites, groups, and studies.
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
Sponsor: Qianfoshan Hospital
Summary
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
Official title: Effectiveness and Safety of Depemokimab in Allergic Bronchopulmonary Aspergillosis (ABPA) With Severe Eosinophilic Asthma(SEA): a Prospective Study of Real-world Experience
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-11-01
Completion Date
2027-08-31
Last Updated
2026-09-24
Healthy Volunteers
No
Interventions
Depemokimab
100 mg (1mL) Subcutaneous Solution
Locations (1)
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
Jinan, Shandong, China